SABCS 2022 Conference Coverage


 

Adjuvant Treatment for HR+/HER2-, Node-Positive, High-Risk eBC: 4-Year Results From the monarchE Study

304 views
February 7, 2023
Comments 0
Login to view comments. Click here to Login